PT-141 10mg

Name: PT-141 10mg
Brand: ProWellness Pharma
Price: 39.99 USD
Availability: InStock

$39.99

$39.99 ~~$49.99~~

Save 20%

Quantity

Size guide

Share

FREE Bacteriostatic Water (30ml) on $150+ orders

*Bacteriostatic Water is needed for reconstitution. Get it here*

PT-141, also known as Bremelanotide, is a synthetic peptide developed to address sexual dysfunction in both men and women. Unlike other treatments for sexual dysfunction, PT-141 works by activating melanocortin receptors in the brain rather than targeting the vascular system. This novel mechanism of action allows PT-141 to stimulate sexual arousal and desire directly through the central nervous system.

Originally derived from the hormone Melanotan II, PT-141 was found to have strong aphrodisiac properties. Researchers isolated this particular effect to create PT-141, focusing on its potential to treat hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction (ED) in men.

Benefits of PT-141 Peptide

Enhanced Sexual Arousal and Desire

PT-141 is primarily known for its ability to increase sexual arousal and desire. It activates melanocortin receptors in the brain, leading to heightened sexual desire and spontaneous sexual arousal. This makes it particularly beneficial for individuals experiencing low libido or sexual interest.

Effective Treatment for Erectile Dysfunction

In men, PT-141 has shown significant promise as a treatment for erectile dysfunction. Unlike traditional ED treatments that focus on increasing blood flow to the genital area, PT-141 works through neural pathways, making it a viable option for those who do not respond well to phosphodiesterase type 5 (PDE5) inhibitors like Viagra or Cialis.

Treatment for Hypoactive Sexual Desire Disorder (HSDD)

PT-141 has been approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This condition is characterized by a persistent lack of sexual desire, causing distress and interpersonal difficulties. PT-141 helps address this issue by directly enhancing sexual desire through its action on the brain.

Rapid Onset of Action

PT-141 is known for its rapid onset of action. When administered via a subcutaneous injection, it can begin to work within 30 to 60 minutes, providing timely relief for those seeking to improve their sexual experiences.

Minimal Side Effects

Compared to other sexual dysfunction treatments, PT-141 has a relatively favorable side effect profile. Common side effects are usually mild and may include nausea, flushing, and headache. The absence of serious cardiovascular side effects makes it a safer alternative for many individuals.

Potential for Treating Other Conditions

Beyond sexual dysfunction, research is exploring the potential of PT-141 to treat other conditions involving the melanocortin system. This includes its possible role in mood regulation and reducing symptoms of stress and anxiety, although more studies are needed in these areas.

Conclusion

PT-141 peptide represents a groundbreaking approach to treating sexual dysfunction, offering a novel mechanism of action through its effects on the brain's melanocortin receptors. Its benefits in enhancing sexual arousal and desire, coupled with its effectiveness in treating erectile dysfunction and hypoactive sexual desire disorder, make it a promising therapy for individuals seeking to improve their sexual health. With ongoing research, the full potential of PT-141 in other therapeutic areas may also be realized.

-Erectile Dysfunction (ED) in Men

Objective: To evaluate PT-141's effectiveness in men with ED unresponsive to PDE5 inhibitors.
Methods: Participants received PT-141 via subcutaneous injection, with erectile function monitored through validated questionnaires and tools.
Results: PT-141 significantly improved erectile function in men who didn't respond to treatments like Viagra, with effects noted within 30 to 60 minutes of administration.

-Hypoactive Sexual Desire Disorder (HSDD) in Women

Objective: To assess PT-141's effectiveness in premenopausal women with HSDD.
Methods: Women diagnosed with HSDD were administered PT-141, with sexual desire and distress levels measured using the Female Sexual Function Index (FSFI) and other scales over time.
Results: PT-141 significantly increased sexual desire and reduced distress in women with low libido, showing sustained effects throughout the treatment period.

-Safety and Tolerability Study

Objective: To investigate PT-141's safety and tolerability in healthy volunteers.
Methods: Healthy male and female participants received various doses of PT-141, with monitoring for physiological responses, adverse effects, and overall tolerability.
Results: PT-141 was generally well-tolerated with minimal side effects, including transient nausea, flushing, and headache, indicating a favorable safety profile for treating sexual dysfunction.

-Long-Term Efficacy Study

Objective: To determine PT-141's long-term efficacy and safety in treating sexual dysfunction.
Methods: Participants with ED or HSDD received PT-141 over an extended period, with regular follow-up visits to assess sexual function, side effects, and overall satisfaction.
Results: PT-141 maintained its efficacy in improving sexual function over time, with sustained increases in sexual desire and arousal. The incidence of side effects did not increase with prolonged use, suggesting PT-141's potential for long-term treatment.

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.